#USA #CFO #Houston #Delphi Diagnostics #Eric Lindquist

Delphi Diagnostics Appoints Eric Lindquist as Chief Financial Officer

Delphi Diagnostics has officially announced the appointment of Eric Lindquist as its new Chief Financial Officer (CFO), effective April 1, 2026. This strategic move comes at a critical juncture for the company as it seeks to further enhance its financial operations and drive growth in the oncology and diagnostics sectors.

Eric Lindquist brings a wealth of experience spanning decades in the pharmaceutical and diagnostics industries. Throughout his career, he has been instrumental in guiding companies through periods of significant change and advancement, which is particularly relevant as Delphi focuses on refining its Endocrine Activity Index® (EAI™) test. This innovative test is designed to better inform treatment decisions for patients battling breast cancer, a critical area within the oncology field.

In his most recent role, Lindquist acted as the Chief Executive Officer of InnoSIGN, where he led a substantial transformation of the company and was pivotal in securing multiple financing rounds—key elements that indicate his capabilities and vision for driving business forward. Before his tenure at InnoSIGN, he served as Chief Business and Commercial Officer at Celcuity, where he successfully managed the acquisition of gedatolisib, advancing it into Phase III trials concentrated on breast cancer treatment.

Lindquist's early career includes senior leadership positions at Natera. There, he contributed to the launch of Signatera, a tailored test for detecting residual disease based on individual cellular signatures. His contributions to Roche also established the company as a leading name in companion diagnostics, where he played a critical role in forming strategic partnerships and driving business development.

In welcoming Lindquist, Winz Casagrande, CEO of Delphi Diagnostics, commented on the significance of his extensive experience at the convergence of oncology, diagnostics, and intricate financial strategies. Casagrande noted, "Eric brings deep expertise at the intersection of oncology, diagnostics, and strategic finance. His experience leading companies through critical milestones will be instrumental as we expand access to EAI and continue to build next-generation breast cancer diagnostics to guide personalized treatment."

Lindquist expressed enthusiasm about his new position, stating, "Delphi Diagnostics is uniquely positioned to transform how treatment decisions are made in breast cancer. The company's biology-driven approach with EAI has the potential to bring greater clarity to complex clinical decisions. I look forward to working with the team to execute its strategy and drive long-term value."

Lindquist holds a Bachelor of Science in Genetics and Cell Biology from the University of Minnesota and an MBA from Capella University. This strong educational background further complements his extensive professional experience, positioning him as an asset within Delphi's leadership team.

The Endocrine Activity Index® (EAI™) Test

The Endocrine Activity Index® (EAI™) test is a pivotal development in personalized medicine for breast cancer, aimed at providing actionable insights for prognosis and predicting the effectiveness of dose-intensive taxane-based chemotherapy in patients diagnosed with stage II-III, HR+ HER2- breast cancer. The EAI assesses the endocrine activity present in breast tumors, offering a refined score proposition that integrates baseline prognostic information through molecular subtype genes and clinical factors, such as tumor size and lymph node involvement.

Research has highlighted the EAI test as a reliable prognostic indicator for long-term patient outcomes in the specified stages of breast cancer, proving itself independent of other existing prognostic assessments. Its capacity to predict responses to dense chemotherapy regimens further enhances its utility in clinical settings.

About Delphi Diagnostics

Headquartered in Texas, Delphi Diagnostics Inc. is at the forefront of developing clinically valid tests that enhance breast cancer treatment strategies. The company proudly holds an exclusive license from The University of Texas MD Anderson Cancer Center to commercialize the Endocrine Activity Index, a technology pioneered by Dr. W. Fraser Symmans. Delphi's mission emphasizes making the EAI test broadly accessible to breast cancer patients, thereby creating new pathways for more personalized and effective breast cancer care. For further information, visit www.delphi-diagnostics.com.

In conclusion, the recruitment of Eric Lindquist as CFO marks an exciting phase for Delphi Diagnostics, reflecting its commitment to innovative advancements in oncology diagnostics and treatment. The forthcoming years promise significant developments as the company seeks to take full advantage of Lindquist's extensive expertise in steering financial strategy and operational growth.